Microarray patches also do not need to be administered by a medical professional and it is expected that volunteers would be able to give the vaccines after only brief training.

Vaccine experts are excited about new clinical trial results for a device that delivers measles vaccine via a "microarray" patch — no syringe needed.

About Vaxxas Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP).

Emory University and Micron Biomedical Launch First-in-Human Clinical Trial of Next-Generation Rotavirus Vaccine Delivered via Dissolvable Microarray Technology ...

Atlanta (June 16 2025)-- Emory University and Micron Biomedical today announced the first clinical trial of a novel rotavirus vaccine, CC24, delivered via dissolvable microarray technology, is now ...